CA3026172A1 - A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer - Google Patents
A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Download PDFInfo
- Publication number
- CA3026172A1 CA3026172A1 CA3026172A CA3026172A CA3026172A1 CA 3026172 A1 CA3026172 A1 CA 3026172A1 CA 3026172 A CA3026172 A CA 3026172A CA 3026172 A CA3026172 A CA 3026172A CA 3026172 A1 CA3026172 A1 CA 3026172A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- sequence
- immune checkpoint
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 130
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 130
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 115
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 115
- 206010028980 Neoplasm Diseases 0.000 title claims description 200
- 201000011510 cancer Diseases 0.000 title claims description 118
- 229960005486 vaccine Drugs 0.000 title description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 438
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 386
- 229920001184 polypeptide Polymers 0.000 claims abstract description 356
- 150000001413 amino acids Chemical class 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims description 131
- 230000028993 immune response Effects 0.000 claims description 119
- 238000011282 treatment Methods 0.000 claims description 88
- 229960005386 ipilimumab Drugs 0.000 claims description 69
- 230000002163 immunogen Effects 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 45
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 40
- 238000002255 vaccination Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 36
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 36
- 229960003301 nivolumab Drugs 0.000 claims description 18
- 150000003384 small molecules Chemical class 0.000 claims description 17
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 15
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 10
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 10
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 9
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 9
- 229950007217 tremelimumab Drugs 0.000 claims description 7
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 3
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 118
- 210000001744 T-lymphocyte Anatomy 0.000 description 136
- 235000001014 amino acid Nutrition 0.000 description 125
- 229940022399 cancer vaccine Drugs 0.000 description 96
- 238000009566 cancer vaccine Methods 0.000 description 96
- 108091008874 T cell receptors Proteins 0.000 description 93
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 93
- 229940024606 amino acid Drugs 0.000 description 89
- 230000005867 T cell response Effects 0.000 description 64
- 230000004044 response Effects 0.000 description 62
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 60
- 150000007523 nucleic acids Chemical class 0.000 description 59
- 108020004707 nucleic acids Proteins 0.000 description 56
- 102000039446 nucleic acids Human genes 0.000 description 56
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 125000003275 alpha amino acid group Chemical group 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 42
- 201000001441 melanoma Diseases 0.000 description 42
- 108010017842 Telomerase Proteins 0.000 description 38
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 31
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 29
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 29
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 27
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 27
- 230000002195 synergetic effect Effects 0.000 description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 22
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 22
- 201000005202 lung cancer Diseases 0.000 description 22
- 208000020816 lung neoplasm Diseases 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000000638 stimulation Effects 0.000 description 22
- 206010060862 Prostate cancer Diseases 0.000 description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108010074708 B7-H1 Antigen Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 101800001271 Surface protein Proteins 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 208000021039 metastatic melanoma Diseases 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 108010058597 HLA-DR Antigens Proteins 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 9
- 102000043129 MHC class I family Human genes 0.000 description 9
- 108091054437 MHC class I family Proteins 0.000 description 9
- 108010033276 Peptide Fragments Proteins 0.000 description 9
- 102000007079 Peptide Fragments Human genes 0.000 description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 9
- 230000006052 T cell proliferation Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000002307 prostate Anatomy 0.000 description 9
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 8
- -1 antibody Chemical class 0.000 description 8
- 238000001516 cell proliferation assay Methods 0.000 description 8
- 210000002443 helper t lymphocyte Anatomy 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 238000011510 Elispot assay Methods 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 108091054438 MHC class II family Proteins 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000002222 downregulating effect Effects 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 230000005746 immune checkpoint blockade Effects 0.000 description 6
- 229940023041 peptide vaccine Drugs 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 102000048776 human CD274 Human genes 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 description 4
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 4
- 102000000763 Survivin Human genes 0.000 description 4
- 108010002687 Survivin Proteins 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000005965 immune activity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010086066 HLA-DR8 antigen Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 102000046158 human CTAG1B Human genes 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 108010057210 telomerase RNA Proteins 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710104662 Enterotoxin type C-3 Proteins 0.000 description 1
- 102100030844 Exocyst complex component 1 Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010060680 GV1001 peptide Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091093094 Glycol nucleic acid Proteins 0.000 description 1
- 229940031764 Gp100:209-217(210M) vaccine Drugs 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010080451 HLA-DQ6 antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
- 206010071019 Prostatic dysplasia Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000001142 lung small cell carcinoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940031734 peptide cancer vaccine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 108700002563 poly ICLC Proteins 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000005211 primary lymphoid organ Anatomy 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| EP16172760.7 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3026172A1 true CA3026172A1 (en) | 2017-12-07 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3026172A Pending CA3026172A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4253419A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7321709B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017275782B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3026172A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3463436T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965957T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3463436T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20231650T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE065176T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3463436T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3463436T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3463436T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65007B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3463436T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017207814A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581649A1 (en) | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| US12251447B2 (en) | 2018-06-29 | 2025-03-18 | Taiho Pharmaceutical Co., Ltd. | Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer |
| WO2022258794A2 (en) | 2021-06-09 | 2022-12-15 | Ultimovacs Ab | A conjugate |
| WO2024083867A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148021A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3581649A1 (en) | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| US9522962B2 (en) | 2010-03-15 | 2016-12-20 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| WO2014036562A2 (en) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| SG10201710472PA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| EA201992251A1 (ru) | 2013-03-15 | 2020-05-08 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| AU2015259516B2 (en) | 2014-05-13 | 2020-05-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3 |
| US20170266270A1 (en) | 2014-05-13 | 2017-09-21 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
| WO2016004213A2 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| EP3166630A4 (en) | 2014-07-07 | 2018-03-28 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016011362A1 (en) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| CN106715458A (zh) | 2014-07-18 | 2017-05-24 | 华盛顿大学 | 癌症疫苗组合物及其使用方法 |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| IL251844B2 (en) | 2014-10-23 | 2024-04-01 | Roussy Inst Gustave | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| CA2954892A1 (en) | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7321709B2 (ja) | 2023-08-07 |
| JP2019517508A (ja) | 2019-06-24 |
| WO2017207814A1 (en) | 2017-12-07 |
| ES2965957T3 (es) | 2024-04-17 |
| EP3463436A1 (en) | 2019-04-10 |
| FI3463436T3 (fi) | 2023-12-04 |
| RS65007B1 (sr) | 2024-01-31 |
| EP3463436B1 (en) | 2023-09-20 |
| SI3463436T1 (sl) | 2024-02-29 |
| US11419927B2 (en) | 2022-08-23 |
| JP2022171684A (ja) | 2022-11-11 |
| DK3463436T3 (da) | 2023-12-18 |
| HUE065176T2 (hu) | 2024-05-28 |
| AU2017275782B2 (en) | 2024-08-15 |
| EP4253419A3 (en) | 2024-05-22 |
| LT3463436T (lt) | 2024-01-25 |
| HRP20231650T1 (hr) | 2024-05-10 |
| US12168045B2 (en) | 2024-12-17 |
| PL3463436T3 (pl) | 2024-03-04 |
| AU2017275782A1 (en) | 2019-01-24 |
| EP4253419A2 (en) | 2023-10-04 |
| US20230049012A1 (en) | 2023-02-16 |
| PT3463436T (pt) | 2023-12-28 |
| US20190247482A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168045B2 (en) | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| US20230277641A1 (en) | Telomerase polypeptide vaccine for treating cancer | |
| Ladjemi et al. | Anti-HER2 vaccines: new prospects for breast cancer therapy | |
| CN111093691A (zh) | 蛋白质抗原及其用途 | |
| EP4045081A1 (en) | Cancer vaccine | |
| Agarwal et al. | Development of novel immune interventions for prostate cancer | |
| WO2024083866A1 (en) | Cancer treatment | |
| Thomas | Development of a prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer | |
| HK40029579A (en) | Protein antigens and uses thereof | |
| HK1177762B (en) | Polypeptides | |
| HK1177762A (en) | Polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220519 |
|
| EEER | Examination request |
Effective date: 20220519 |
|
| EEER | Examination request |
Effective date: 20220519 |
|
| EEER | Examination request |
Effective date: 20220519 |
|
| EEER | Examination request |
Effective date: 20220519 |